Vosoritide · VOXZOGO
Peptide
Evidence outlook
Approved: Achondroplasia
Regulatory approval supersedes design-level evidence grading; the trials behind approval are preserved below as the drug's evidence history.
track record: Reliable signal
Also in development:Hypochondroplasia · Phase 3 · investigational in the US · filing submitted
Also approved (2)
- Achondroplasia in children whose growth plates are not closed
- Achondroplasia in patients 4 months of age and older whose epiphyses are not closed
How the evidence outlook works ↗
Featured trials
The studies most instrumental to this drug's clinical progression, individually graded on design and result. The complete registry, including every study not featured here, is listed below.
| Trial | Phase | Endpoint | Key result | Signal | Source |
|---|---|---|---|---|---|
NCT03197766 NCT03197766 · Achondroplasia This was a randomized, triple-blind, placebo-controlled trial of 121 children, with 60 receiving vosoritide and 61 receiving placebo. The hard clinical primary endpoint—change in annualized growth velocity at Week 52—was met in favor of vosoritide, with a statistically significant difference (p<0.0001). Registry: NCT03197766 | 3 | Change From Baseline in Annualized Growth Velocity (AGV) at Week 52 (At Baseline and Week 52) 2019-10-30 | Change From Baseline in Annualized Growth Velocity (AGV) at Week 52 (At Baseline and Week 52): BMN 111 - 15 μg/kg 1.71 cm/year (95% CI 1.4 to 2.01) | Placebo 0.13 cm/year (95% CI -0.18 to 0.45) | Reliable signal | link ↗ |
View 1 more trial
NCT03424018 NCT03424018 · Achondroplasia Registry: NCT03424018 | 3 | Change from baselines in mean annualized growth velocity (Through study completion, an average of 1 year) 2031-06 | In progress: results expected 1 Jun 2031 | not yet graded | link ↗ |
All registered studies
Every ClinicalTrials.gov study of this drug's own program. Studies backing a featured trial above are marked Featured; the rest aren't individually graded. Filter by which indication a study was run for, then browse by phase. Studies where this drug served as another program's comparator, or is merely referenced, are listed separately below.
Phase 3 (4)
What this study did
What this study did
What this study did
What this study did
Phase 2 (10)
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
Phase 1/2 (1)
What this study did
Phase 1 (2)
What this study did
What this study did
Used as active comparator (1)
Other programs' studies in which this drug was the registered active-comparator arm: a marker of standard-of-care status, not evidence of this drug's own progression.
Phase 2/3 (1)
What this study did
Competitive landscape
This drug's own stage for Achondroplasia: Approved. Competitors below are sorted furthest-along first.
| Drug | Stage | Modality | Mechanism | Evidence signal | Reported efficacygraded featured trials | |
|---|---|---|---|---|---|---|
| Vosoritide (VOXZOGO): this drug | Approved | Peptide | Natriuretic peptide receptor B (NPR-B) | Reliable signal | NCT03197766: Change From Baseline in Annualized Growth Velocity (AGV) at Week 52 (At Baseline and Week 52): BMN 111 - 15 μg/kg 1.71 cm/year (95% CI 1.4 to 2.01) | Placebo 0.13 cm/year (95% CI -0.18 to 0.45) | |
| BMN 333 | Phase 2/3 | Peptide | C-type natriuretic peptide (CNP) pathway | not yet graded | No reviewed efficacy summary in this indication | |
| Lavengratinib | Phase 1/2 | Small molecule | FGFR2 / FGFR3 | not yet graded | No reviewed efficacy summary in this indication |
Upcoming events
(7 total)
Estimated primary-completion dates from ClinicalTrials.gov. These are registry estimates, never confirmed readout dates; they can move as trials progress.
Follow VOXZOGO (Vosoritide) to get an email as a readout nears, when a date moves, or when a study changes status. Needs a free account.
Add these readouts to your calendar: Apple or Outlook · Google Calendar · .ics link. The calendar updates when a registry date moves.
2027 (2)
2028 (2)
2031 (1)
June 2031 (1)
What to watch
2038 (1)
May 2038 (1)
What to watch
2044 (1)
October 2044 (1)
What to watch
Regulatory and conference events
(3)
Filings, regulator decisions, scientific presentations, topline results and licensing deals, each from a dated source. When a source gives only the month, the month is shown.
Coming up
Recent